Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, observational study to assess clinical effectiveness of Gla-300 in a cohort of UK patients with type 1 diabetes (T1D)

Trial Profile

A retrospective, observational study to assess clinical effectiveness of Gla-300 in a cohort of UK patients with type 1 diabetes (T1D)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SPARTA
  • Most Recent Events

    • 25 Oct 2018 Results published in the Diabetic Medicine
    • 24 Apr 2018 New trial record
    • 20 Mar 2018 Primary endpoint has been met. (Change in HbA1c levels from baseline to Month 6 after the initiation of Gla-300) as per result presented at The 100th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top